跳至主要内容
临床试验/NCT04675775
NCT04675775已完成不适用

Medically-Tailored Meals to Prevent Recurrent Hepatic Encephalopathy: The BRAINFOOD Pilot Trial

University of Michigan1 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2021年1月21日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
17
试验地点
1
主要终点
Overall Participant Retention Rate Based on Proportion of Participants Who Complete All Study Visits

研究概览

简要总结

This study is being completed for patients with cirrhosis, including patients with a prior history of hepatic encephalopathy (HE) to evaluate the feasibility and benefits of medically-tailored meals as an intervention.

Patients will be enrolled from the University of Michigan and will complete the baseline assessments in-person or remotely. In addition participants will complete study related materials before, during and after treatment with medically-tailored meals (MTM). After completing the study meals, participants will return for follow-up or have this visit completed remotely as well as have an observational period for 12 more weeks.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Diagnosis of cirrhosis will be based upon:
  • •liver biopsy, OR
  • •history of cirrhosis complication: ascites, variceal bleeding, hepatic encephalopathy, OR
  • •2 of the following 4 criteria:
  • •Ultrasound, Computed tomography (CT), or Magnetic resonance imaging (MRI) findings of cirrhosis (cirrhotic appearing liver, splenomegaly, varices, ascites)
  • •Fibroscan liver stiffness score >13 kilopascals (kPa)
  • •Laboratory testing: aspartate aminotransferase/platelet ratio index (APRI) >2.0
  • •CT, MRI or esophagogastroduodenoscopy (EGD) showing presence of esophageal varices
  • •Patients with history of > grade 2 HE within 180 days of enrollment based on review of clinical documentation verifying the event. If a description of HE symptoms is provided in clinical documentation, but it is unclear if it meets Grade 2 criteria, the principal investigator will assess the clinical documentation and provide an HE grade.

排除标准

  • •Non-English speaking
  • •Model for End-Stage Liver Disease (MELD) Score > 20
  • •Pregnancy (self-reported)
  • •Unable or unwilling to provide consent
  • •History of liver transplant
  • •Current or planned admission to a nursing facility
  • •Serum creatinine > 2.0 milligrams per deciliter (mg/dL) (with the exception that we will include patients with a serum creatinine > 2.0 mg/dL if they are receiving hemodialysis)
  • •Disorientation at the time of enrollment
  • •Barcelona-Clinic Liver Cancer (BCLC) Stage D Hepatocellular Carcinoma with Child-Turcotte-Pugh (CTP) Class C
  • •History of eating disorder

研究组 & 干预措施

Medically-tailored meals

Experimental

Participants will receive meals that adhere to their specified nutritional targets dependent upon their cirrhosis complication of hepatic encephalopathy (HE) and/or ascites. Participants with HE will receive high-protein (approximately 1 gram of medication per kilogram of the body weight (1g/kg/day) and high-calorie (approximately 30c/kg/day) meals. Participants with HE and ascites will receive high-protein and high-calorie meals that are also low-sodium (less than or equal to 2000 milligrams a day).

干预措施: Medically-tailored meals (MTM) (Other)

Medically-tailored meals

Experimental

Participants will receive meals that adhere to their specified nutritional targets dependent upon their cirrhosis complication of hepatic encephalopathy (HE) and/or ascites. Participants with HE will receive high-protein (approximately 1 gram of medication per kilogram of the body weight (1g/kg/day) and high-calorie (approximately 30c/kg/day) meals. Participants with HE and ascites will receive high-protein and high-calorie meals that are also low-sodium (less than or equal to 2000 milligrams a day).

干预措施: Protein supplements (Dietary Supplement)

Medically-tailored meals

Experimental

Participants will receive meals that adhere to their specified nutritional targets dependent upon their cirrhosis complication of hepatic encephalopathy (HE) and/or ascites. Participants with HE will receive high-protein (approximately 1 gram of medication per kilogram of the body weight (1g/kg/day) and high-calorie (approximately 30c/kg/day) meals. Participants with HE and ascites will receive high-protein and high-calorie meals that are also low-sodium (less than or equal to 2000 milligrams a day).

干预措施: Nutrition education handout (Behavioral)

结局指标

主要结局

Overall Participant Retention Rate Based on Proportion of Participants Who Complete All Study Visits

时间窗: up to 27 weeks post enrollment

Overall participant retention rate based on proportion of participants who completed all study visits

Participant Adherence Rate to Medically-Tailored Meals (MTM)

时间窗: up to 11 weeks post enrollment

The participant adherence rate to MTM based on proportion of participants who consumed ≥75% of delivered meals and evening snack

次要结局

  • Proportion of Participants Who Completed All Study Assessments and Procedures(up to 27 weeks post enrollment)
  • Eligible Candidates Who Enrolled After Screening(approximately 1 year (enrollment period))
  • The Percentage of Enrolled Participants Who Dropped Out of Study(up to 27 weeks)
  • Time Required to Complete Assessments(Up to 90 minutes)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Elliot B. Tapper

Assistant Professor of Internal Medicine

University of Michigan

研究点 (1)

Loading locations...

相似试验

The BRAINFOOD Trial to Prevent Recurrent Hepatic... | 临床试验